Showing results (21-30 of 540) with videos related to
Sort By:
Pageof 54
Frontiers in Cardiovascular Medicine|May 22, 2019
Assessment of PEEP-Ventilation and the Time Point of Parallel-Conductance Determination for Pressure-Volume Analysis Under β-Adrenergic Stimulation in MiceLucas Bacmeister, Sebastian Segin, Rebekka Medert, et al.Annals of Translational Medicine|October 27, 2018
Beyond conventional secondary prevention in coronary artery disease-what to choose in the era of CANTOS, COMPASS, FOURIER, ODYSSEY and PEGASUS-TIMI 54? A review on contemporary literatureDaniel Kalbacher, Christoph Waldeyer, Stefan Blankenberg, et al.BMJ Case Reports|September 24, 2014
Fatal recurrence of fulminant giant cell myocarditis and recovery after initialisation of an alternative immunosuppressive regimeNina Fluschnik, Felicitas Escher, Stefan Blankenberg, et al.ESC Heart Failure|August 4, 2017
Right ventricular temporal assist device for cardiac recompensationIsabell Yan, Hanno Grahn, Stefan Blankenberg, et al.World Journal of Cardiology|January 6, 2016
Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fractionChristian Schulte, Dirk Westermann, Stefan Blankenberg, et al.European Heart Journal. Cardiovascular Pharmacotherapy|June 5, 2025
The role of cangrelor in acute and high-risk PCI settingsUwe Zeymer, Tobias Geisler, Dirk Westermann, et al.Journal of the American Heart Association|July 11, 2024
Serum Concentrations of Matrix Metalloproteinase-1 and Procollagen Type I Carboxy Terminal Propeptide Discriminate Infarct-Like Myocarditis and Non-ST-Segment-Elevation Myocardial InfarctionLucas Bacmeister, Ersin Cavus, Sebastian Bohnen, et al.World Journal of Cardiology|September 29, 2015
Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?"Peter Moritz Becher, Nina Fluschnik, Stefan Blankenberg, et al.Current Pharmaceutical Biotechnology|January 28, 2012
Diastolic heart failure and LV dyssynchronyMario Kasner, Dirk Westermann, Heinz-Peter Schultheiss, et al.Integrated Blood Pressure Control|September 28, 2011
First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combinationKonstantinos Savvatis, Dirk Westermann, Heinz-Peter Schultheiss, et al.Pageof 54